Nothing said here yet.
to join the conversation.
| King-Jones HeidySee Remarks | Sell | 16,605 | $1.5M | Thu, Oct 1 |
| King-Jones HeidySee Remarks | Sell | 7,228 | $660.3K | Thu, Oct 1 |
| Turtle CameronChief Executive Officer | Sell | 4,990 | $465.9K | Thu, Oct 1 |
| Turtle CameronChief Executive Officer | Sell | 3,989 | $368.2K | Thu, Oct 1 |
| Burrows Scott LChief Financial Officer | Sell | 3,071 | $285.4K | Thu, Oct 1 |
| King-Jones HeidySee Remarks | Sell | 2,600 | $243.0K | Thu, Oct 1 |
| Turtle CameronChief Executive Officer | Sell | 2,683 | $241.7K | Thu, Oct 1 |
| Turtle CameronChief Executive Officer | Sell | 2,638 | $241.3K | Thu, Oct 1 |
| King-Jones HeidySee Remarks | Sell | 2,100 | $194.7K | Thu, Oct 1 |
| Burrows Scott LChief Financial Officer | Sell | 2,100 | $193.0K | Thu, Oct 1 |
| Burrows Scott LChief Financial Officer | Sell | 1,500 | $135.4K | Thu, Oct 1 |
| Turtle CameronChief Executive Officer | Sell | 600 | $53.5K | Thu, Oct 1 |
Spyre Therapeutics has seen its share price move sharply in recent years, so the question now is whether a US$90.33 stock is adequately supported by what sits on its balance sheet.
Spyre Therapeutics' (SYRE) combination therapy approach for inflammatory bowel disease gained furthe
Spyre Therapeutics (NasdaqGS:SYRE) completed a public stock offering raising about US$350 million to fund its drug pipeline. The equity raise is aimed at advancing clinical programs in gastroenterology, rheumatology, and dermatology indications.
Key TakeawaysSpyre Therapeutics shares fell 14% after the company sold $350 million of stock at $85 a share, about 8% below Monday’s close. The deal was upsized from a reported $250 million and adds roughly 5% more stock.
Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company's announcement of an underwritten public offering of its common stock.